🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT06863025
Active, not recruiting Not applicable

Effects of Neurofeedback Training on Attentional Deficits in Patients With Acquired Brain Injury

NCT06863025 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospitales Nisa
Phase
Not applicable
Started
2024-10-01
Last updated
2025-03-07

Condition(s) studied

Brain InjuriesAttention Disorder

Investigational drug(s) / intervention(s)

Neurofeedback trainingStandard cognitive therapy

Neurofeedback training: Neurofeedback (NF) or electroencephalographic feedback (EEG) training refers to a type of computerized cognitive training that changes EEG patterns through operant conditioning. NF is a computerized rehabilitation technique but also a non-invasive neuromodulation approach, as it alters brain activity by delivering a stimulus. It is well-established for the treatment of conditions such as anxiety and ADHD. During NF rehabilitative training, the subject is provided with real-time EEG feedback, usually with a visual or auditory stimulus, with the aim of normalizing brain oscillations. Rehabilitation through NF training generally targets EEG frequencies that are affected and underlie the observed behavioral deficit (e.g., attentional dysfunctions).

Standard cognitive therapy: This is the control intervention and it involves standard practice cognitive therapy in neurorehabilitation. Neuropsychologists and other clinicians test and train the patients' cognitive specific aspect (in this case, attention) with some validated tools and/or games

Study summary

The goal of this study is to investigate new neuromodulation therapies for attention deficits following acquired brain injury. Brain damage can affect various domains, including motor and cognitive functions. However, cognitive deficits have many consequences on the functionality and independence of patients, and attention is an essential requirement for most of daily activities. After brain damage, cognitive rehabilitation is generally the first treatment option for attention deficits. Some studies have shown that cognitive rehabilitation is sometimes not very effective.

For this reason, new therapies such as neuromodulation techniques are being investigated. Neurofeedback is a non-invasive neuromodulation therapy involving a type of computer-based training and learning, and some studies have shown that it is a promising tool to treat cognitive deficits in patients with brain injuries.

In the present study, the investigators will evaluate the effects of neurofeedback as a therapy for attentional deficits after brain injury. Participants undergoing neurofeedback and cognitive therapy will be compared to participants only receiving cognitive therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * ≥18 years old * ABI resulting from TBI, stroke, hypoxia and other etiologies * attentional deficits that are among the objectives of neurorehabilitation as established by the clinical team (scores falling in the 90% percentiles on the Conner's Continuous Performance - CCPT, on the Digit and Spatial Span Tasks and Color Trail test) * good cognitive condition (ie., scores of ≥23 in the Mini Mental State Examination * MMSE or ≥75 in the Galveston Orientation \& Amnesia Test - GOAT) Exclusion Criteria: * previous report of psychiatric and/or neurologic disorders * contraindication to computerized activities * blindness or severe visual impairments

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Irenea Neurorhb Sl Valencia Province de Valence
Servicio de Neurorrehabilitación y Daño Cerebral de los Hospitales NISA Valencia Spain

More Hospitales Nisa trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06863025 on ClinicalTrials.gov ↗ ← All trials in Spain